

Investor Relations and Corporate Communications



Building Strategic Visibility and Enterprise Value for Breakthrough Data Readouts

THE CHANGE THEY WANTED


- ✓ Increase **IR visibility** and **shareholder value** for an international company focused on CNS disorders, with a potential breakthrough therapy for a disease impacting nearly 1% of the world's population
- ✓ Develop investor, KOL and strategic partner understanding for the **commercial potential** of evenamide and its unique mechanism of action impacting schizophrenia and **treatment-resistant schizophrenia**
- ✓ Rebuild **investor credibility** following an earlier late-stage trial failure that decimated Newron's market cap

WHAT WE DID

- ✓ Counseled management on a strategic investor and media relations approach, carefully **implemented over 9 months**
- ✓ Orchestrated the disclosure, messaging, scientific presentation and investor teleconference approaches for **three successive data readouts** that demonstrated increasingly convincing efficacy and safety for evenamide in treatment-resistant schizophrenia
- ✓ Built awareness, visibility through **global media outreach** for evenamide's novel MOA and potential as an add-on therapy to **all current schizophrenia therapies**
- ✓ Utilized LHS Reach™ to target U.S. and international investment community and secured **high-impact meetings** at the largest U.S. biotech investor conferences

THE CHANGE WE DELIVERED

- ✓ Increased awareness of evenamide's therapeutic potential and repositioned Newron with **near-term commercial opportunities** and long-term pipeline
- ✓ More than **50** high-impact one-on-one meetings with investors at JP Morgan and BIO CEO conferences
- ✓ **Four** strategic partnering meetings with global pharma companies for Newron's evenamide asset
- ✓ **15** high-profile media articles with over 35 million global reader impressions
- ✓ Newron's share price and market cap increased by over **500%** in 9 months



Increasing IR visibility and shareholder value




LABIOTECH.eu

Newron reports 'striking' schizophrenia study results

AP **MORNINGSTAR** **Seeking Alpha** **finanznet**

CINP 33rd CINP Hybrid World Congress of Neuropsychopharmacology
9-13 June 2022 Virtual & Taipei, Taiwan



BIOTECH

Newron's shares accelerate as one-year schizophrenia data boosts chances of historic approval

By Nick Paul Taylor - Feb 15, 2023 09:30am

FIERCHE Biotech

41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Bio **CEO & INVESTOR** CONFERENCE

Scrip Pharma Intelligence

Newron Points 'Future Value-Driver' Evenamide At Drug-Resistant Schizophrenia

Following Phase II Promise

proactive

Newron Pharmaceuticals teases update on "unheard of" trial results

Newron Pharmaceuticals teases update on "unheard of" trial results

Watch later Share

MORE VIDEOS

pharmaphorum

JP Morgan 2023 - Stefan Weber and Ravi Anand

Meetings with Key Investors

ATHYRIUM **Stephens**

BTIG **HCW** H.C. WAINWRIGHT & CO.

BARINGS **WEDBUSH**

VIVO CAPITAL **AGP** Alliance Global Partners

BERENBERG CAPITAL MARKETS **Hutton**

ROTH Capital Partners

BioSpace

Newron's Schizophrenia Candidate Gets Better Over Time

the pharma letter

* Up to date news for the Pharmaceutical and Biotechnology industries

TODAY'S ISSUE

Newron reports striking one-year interim efficacy results evaluating evenamide